Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1α,25-Dihydroxyvitamin D3 in Mice

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drug Metabolism And Disposition

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/dmd.115.067033PMID 26586377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PKPD modelling to predict altered disposition of 1α,25‐dihydroxyvitamin D3 in mice due to dose‐dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation

  2015cited by this paper
• 1α,25-Dihydroxyvitamin D3 Reduces Cerebral Amyloid-β Accumulation and Improves Cognition in Mouse Models of Alzheimer's Disease

  2014cited by this paper
• Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model

  2014cited by this paper
• Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.

  2014cited by this paper
• Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.

  2013cited by this paper
• Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies

  2013cited by this paper
• Commentary: Theoretical Predictions of Flow Effects on Intestinal and Systemic Availability in Physiologically Based Pharmacokinetic Intestine Models: The Traditional Model, Segregated Flow Model, and QGut Model

  2012cited by this paper
• Applications of minimal physiologically-based pharmacokinetic models

  2012cited by this paper
• 1α,25-Dihydroxyvitamin D3 Up-Regulates P-Glycoprotein via the Vitamin D Receptor and Not Farnesoid X Receptor in Both fxr(−/−) and fxr(+/+) Mice and Increased Renal and Brain Efflux of Digoxin in Mice In Vivo

  2011cited by this paper
• Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models

  2010influential reference
• PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism.

  2010cited by this paper
• Vitamin D status: measurement, interpretation, and clinical application.

  2009cited by this paper
• The anti‐inflammatory effects of 1,25‐dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin‐mediated T lymphocyte homing

  2004cited by this paper
• Diversity of mechanism-based pharmacodynamic models.

  2003cited by this paper
• Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).

  2003cited by this paper
• The 25(OH)D3/1α,25(OH)2D3-24R-hydroxylase: a catabolic or biosynthetic enzyme?

  2001cited by this paper
• The 25(OH)D(3)/1alpha,25(OH)(2)D(3)-24R-hydroxylase: a catabolic or biosynthetic enzyme?

  2001cited by this paper
• 1,25-Dihydroxyvitamin D3– a hormone with immunomodulatory properties

  2000cited by this paper
• A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism.

  2000cited by this paper
• Route-Dependent Metabolism of Morphine in the Vascularly Perfused Rat Small Intestine Preparation

  2000cited by this paper
• Targeted inactivation of vitamin D hydroxylases in mice.

  1999cited by this paper
• Renal and Nonrenal 25‐Hydroxyvitamin D‐1α‐Hydroxylases and Their Clinical Significance

  1998cited by this paper
• Current understanding of the molecular actions of vitamin D.

  1998influential reference
• Lumping of Whole-Body Physiologically Based Pharmacokinetic Models

  1998cited by this paper
• Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

  1997cited by this paper
• Characterization of four basic models of indirect pharmacodynamic responses

  1996cited by this paper
• Expression of the 1,25‐dihydroxyvitamin D3‐24‐hydroxylase gene in rat intestine: Response to calcium, vitamin D3 and calcitriol administration in vivo

  1995cited by this paper
• Calculating predictive performance: a user's note.

  1995cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• 1 beta, 25 (OH)2-vitamin D3 is an antagonist of 1 alpha,25 (OH)2-vitamin D3 stimulated transcaltachia (the rapid hormonal stimulation of intestinal calcium transport).

  1992cited by this paper
• 1β, 25(OH)2-vitamin D3 is an antagonist of 1α,25(OH)2-vitamin D3 stimulated transcaltachia (The rapid hormonal stimulation of intestinal calcium transport)

  1992cited by this paper
• Parathyroid hormone inhibits 25-hydroxyvitamin D3-24-hydroxylase mRNA expression stimulated by 1 alpha,25-dihydroxyvitamin D3 in rat kidney but not in intestine.

  1992cited by this paper
• Production and degradation of calcitriol in renal failure rats.

  1987influential reference
• Interaction of 1,25-dihydroxyvitamin-D3 with keratinocytes and fibroblasts from skin of normal subjects and a subject with vitamin-D-dependent rickets, type II: a model for study of the mode of action of 1,25-dihydroxyvitamin D3.

  1983cited by this paper
• Some suggestions for measuring predictive performance

  1981cited by this paper
• Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models

  1979cited by this paper
• Vitamin D-3 intestinal absorption in vivo: influence of fatty acids, bile salts, and perfusate pH on absorption.

  1978cited by this paper
• Statistical estimations in pharmacokinetics

  1974influential reference

• Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors

  2024influential citation
• Canadian Content in the Pages of Drug Metabolism and Disposition: A Comprehensive Historical Analysis

  2023cites this paper
• Novel Approach for the Approximation of Vitamin D3 Pharmacokinetics from In Vivo Absorption Studies

  2023cites this paper
• Physiologically Based Pharmacokinetic Modeling of Vitamin D3 and Metabolites in Vitamin D–Insufficient Patients

  2022cites this paper
• Effects of Simulated Weightlessness on Metabolizing Enzymes and Pharmacokinetics of Folic Acid in SD Rats.

  2021cites this paper
• Protection by vitamin D against high-glucose-induced damage in retinal pigment epithelial cells.

  2020cites this paper
• Noteworthy idiosyncrasies of 1α,25-dihydroxyvitamin D3 kinetics for extrapolation from mouse to man: Commentary.

  2020cites this paper
• Vitamin D Metabolism and Guidelines for Vitamin D Supplementation.

  2020cites this paper
• Highlighting Vitamin D Receptor–Targeted Activities of 1α,25-Dihydroxyvitamin D3 in Mice via Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling

  2018influential citation
• Potencies of vitamin D analogs, 1α‐hydroxyvitamin D3, 1α‐hydroxyvitamin D2 and 25‐hydroxyvitamin D3, in lowering cholesterol in hypercholesterolemic mice in vivo

  2018cites this paper
• Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.

  2017cites this paper
• PBPK Modeling to Estimate Metabolite Formation From First-Pass Organs: Intestine and Liver

  2017cites this paper
• A physiologically based pharmacokinetic model of vitamin D

  2017influential citation
• Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport

  2016cites this paper